Automatically Assembling the Building Blocks of Cellular Circuitry
|
|
- Elisabeth Jennings
- 5 years ago
- Views:
Transcription
1 Motivation Automatically Assembling the Building Blocks of Cellular Circuitry T. M. Murali April 20, 2006
2 Motivation Features of the Wiring iagram iagram is multi-modal. iagram is incomplete. Changes from organism to organism with evolutionary pressures acting as constraints. Wiring iagram is static. Not all interactions in the cell are active at all times. Set of active interactions changes with time, signals from other cells, environmental changes, attacks from pathogens,....
3 Motivation ynamic Views of the Cellular Wiring iagram Measure molecular concentrations in different conditions. Most common type of measurement is gene expression.
4 Motivation ynamic Views of the Cellular Wiring iagram Measure molecular concentrations in different conditions. Most common type of measurement is gene expression. Overlay gene expression data on the wiring diagram to obtain a dynamic view. Compare dynamic views for different conditions. How does the cellular network rewire itself under different conditions?
5 Motivation Previous Research ate hubs and party hubs. Purely topological changes in regulatory network structure across a small number of conditions Luscombe et al., Nature Most previous work focusses on rewiring at the level of single nodes or edges. Existing methods focus on the hierarchical organisation of modules in the universal network Ravasz et al., Science 2002; Tanay et al., PNAS, 2004.
6 Approach Overall Pipeline: Stage 1 Protein protein interaction networks Transcriptional regulatory networks Metabolic pathways Heat shock Form Universal network Experiments Cold shock Osmotic shock Sporulation Compute active networks Rapamycin
7 Approach Overall Pipeline: Stage 2 Compute NetworkLegos H C O H C O S R Active networks for each condition H C S R Network legos Network formulae sag 1. Automatically combine active networks via set-theoretic expressions. 2. Each expression is associated with a set of cell states (and their active networks) and has two interpretations: 2.1 A boolean formula that relates (the active networks of) a subset of the cell states using intersection and difference operations on graphs. 2.2 A network lego, a sub-network obtained by combining the active networks associated with the expression as decreed by the operators in the expression.
8 Approach Toy Example of Network Legos a c e a c e a c e b d b d b d Cell state A Cell state B Cell state C
9 Approach Toy Example of Network Legos a c e a c e a c e b d b d b d Cell state A Cell state B Cell state C a c A B C b d NetworkFormula NetworkLego
10 Approach sag H C O H C O S R H C S R Network legos Network formulae sag Each binary expression tree for a formula is a directed graph. sag is the AG formed by the union of all these trees. Leaves of the sag are the cell states (and the associated active networks). Each internal node of the sag is a formula recursively built by
11 Approach Novel Features of Our Approach Combined representation of biological processes using formulae and network legos. A formula relates different cellular states or perturbations by explicitly denoting their participation in a formula via intersections and differences. Each formula corresponds to a network lego, a functional module of coherently interacting genes in the universal network. sag puts all cell states/conditions in context with respect to each other in a hierarchical representation.
12 efinitions Basic efinitions Given two graphs G 1 and G 2, the intersection G 1 G 2 is the graph induced by the edges that occur in both. Their difference G 1 G 2 is the graph induced by the edges that occur in G 1 but not in G 2.
13 efinitions Problem Setting nput: U is the universal network of interactions. For each cell state s, A s U is the set of all interactions active in s. A is the set of all active networks. Output: A set of formulae and associated network legos The sag formed by the union of all the formulae The statistical significance and functional enrichment of each formula (network lego).
14 efinitions efinition of Network Legos and Formulae a c A B C b d NetworkFormula NetworkLego Each network lego L associated with a set A L of active networks. efine network legos and formulae recursively in parallel:
15 efinitions efinition of Network Legos and Formulae a c A B C b d NetworkFormula NetworkLego Each network lego L associated with a set A L of active networks. efine network legos and formulae recursively in parallel: 1. f N A, then N is a network lego with A N = {N}.
16 efinitions efinition of Network Legos and Formulae a c A B C b d NetworkFormula NetworkLego Each network lego L associated with a set A L of active networks. efine network legos and formulae recursively in parallel: 1. f N A, then N is a network lego with A N = {N}. 2. f L and M are network legos, then L M is a network lego with A L M = A L A M.
17 efinitions efinition of Network Legos and Formulae a c A B C b d NetworkFormula NetworkLego Each network lego L associated with a set A L of active networks. efine network legos and formulae recursively in parallel: 1. f N A, then N is a network lego with A N = {N}. 2. f L and M are network legos, then L M is a network lego with A L M = A L A M. 3. f L and M are network legos, then L M is a network lego with A L M = A L A M.
18 efinitions efinition of Network Legos and Formulae a c A B C b d NetworkFormula NetworkLego Each network lego L associated with a set A L of active networks. efine network legos and formulae recursively in parallel: 1. f N A, then N is a network lego with A N = {N}. 2. f L and M are network legos, then L M is a network lego with A L M = A L A M. 3. f L and M are network legos, then L M is a network lego with A L M = A L A M. 4. Require A L A M = to prevent trivial formulae. Skip statistical significance
19 efinitions Statistical Significance of a Network Lego The size σ(l) of a network lego is the number of edges in L. σ(l) depends on the number of networks in A that are combined in the corresponding formula. t is not appropriate to compare different network legos based on their sizes.
20 efinitions Statistical Significance of a Network Lego The size σ(l) of a network lego is the number of edges in L. σ(l) depends on the number of networks in A that are combined in the corresponding formula. t is not appropriate to compare different network legos based on their sizes. To put all network legos on an equal footing, we compute the statistical significance of each network lego.
21 efinitions Statistical Significance of a Network Lego The size σ(l) of a network lego is the number of edges in L. σ(l) depends on the number of networks in A that are combined in the corresponding formula. t is not appropriate to compare different network legos based on their sizes. To put all network legos on an equal footing, we compute the statistical significance of each network lego. Suppose we observe a network lego with k edges. What is the probability that we will observe a network lego with k or more edges if the active networks were constructed at random?
22 efinitions Statistical Significance of a Network Lego The size σ(l) of a network lego is the number of edges in L. σ(l) depends on the number of networks in A that are combined in the corresponding formula. t is not appropriate to compare different network legos based on their sizes. To put all network legos on an equal footing, we compute the statistical significance of each network lego. Suppose we observe a network lego with k edges. What is the probability that we will observe a network lego with k or more edges if the active networks were constructed at random? We compute the statistical significance of a network lego under the null hypothesis that 1. each network N in A is formed by selecting each edge in N uniformly at random without replacement and 2. each network N in A is selected independently from the other networks in A.
23 efinitions Statistical Significance: a Simple Case Consider the formula L = A B, where A, B A.
24 efinitions Statistical Significance: a Simple Case Consider the formula L = A B, where A, B A. For an edge e U, let X e be a binary random variable denoting the event that e is selected in L under the null hypothesis.
25 efinitions Statistical Significance: a Simple Case Consider the formula L = A B, where A, B A. For an edge e U, let X e be a binary random variable denoting the event that e is selected in L under the null hypothesis. X e = 1 if and only if e is selected in A and in B.
26 efinitions Statistical Significance: a Simple Case Consider the formula L = A B, where A, B A. For an edge e U, let X e be a binary random variable denoting the event that e is selected in L under the null hypothesis. X e = 1 if and only if e is selected in A and in B. Pr(X e = 1) = σ(a) σ(b) σ(u) σ(u). This probability is equal for all edges e U. enote the probability by p L.
27 efinitions Statistical Significance: Another Simple Case Consider the formula M = A B.
28 efinitions Statistical Significance: Another Simple Case Consider the formula M = A B. For an edge e U, let X e be a binary random variable denoting the event that e is selected in M = A B under the null hypothesis.
29 efinitions Statistical Significance: Another Simple Case Consider the formula M = A B. For an edge e U, let X e be a binary random variable denoting the event that e is selected in M = A B under the null hypothesis. X e = 1 if and only if e is selected in A but not in B. Pr(X e = 1) = σ(a) σ(u) 1 σ(b). σ(u) This probability p M is equal for all edges e U.
30 efinitions Statistical Significance: the General Case Extend these arguments to formulae involving more than two networks in A.
31 efinitions Statistical Significance: the General Case Extend these arguments to formulae involving more than two networks in A. Consider the formula H = L M. By definition, any network in A appears either in L or in M or in neither.
32 efinitions Statistical Significance: the General Case Extend these arguments to formulae involving more than two networks in A. Consider the formula H = L M. By definition, any network in A appears either in L or in M or in neither. An edge e is selected in H if and only if e is selected in L and in M.
33 efinitions Statistical Significance: the General Case Extend these arguments to formulae involving more than two networks in A. Consider the formula H = L M. By definition, any network in A appears either in L or in M or in neither. An edge e is selected in H if and only if e is selected in L and in M. p H = p L p M
34 efinitions Statistical Significance: the General Case Extend these arguments to formulae involving more than two networks in A. Consider the formula H = L M. By definition, any network in A appears either in L or in M or in neither. An edge e is selected in H if and only if e is selected in L and in M. p H = p L p M Similarly, if H = L M, then e is selected in H if and only if e is selected in L but not in M. p H = p L (1 p M )
35 efinitions Statistical Significance: the General Case Extend these arguments to formulae involving more than two networks in A. Consider the formula H = L M. By definition, any network in A appears either in L or in M or in neither. An edge e is selected in H if and only if e is selected in L and in M. p H = p L p M Similarly, if H = L M, then e is selected in H if and only if e is selected in L but not in M. p H = p L (1 p M ) n both cases, we can compute p H by recursively computing p L and p M.
36 efinitions Statistical Significance: Completing the Analysis For a formula H, p H is the probability that an edge will be selected in H under the null hypothesis. The number of edges in H is σ(h) = e U X e.
37 efinitions Statistical Significance: Completing the Analysis For a formula H, p H is the probability that an edge will be selected in H under the null hypothesis. The number of edges in H is σ(h) = e U X e. σ(h) has mean σ(u)p H and variance σ(u)p H (1 p H ).
38 efinitions Statistical Significance: Completing the Analysis For a formula H, p H is the probability that an edge will be selected in H under the null hypothesis. The number of edges in H is σ(h) = e U X e. σ(h) has mean σ(u)p H and variance σ(u)p H (1 p H ). The statistical significance of H is Pr( σ(h) σ(h)).
39 efinitions Statistical Significance: Completing the Analysis For a formula H, p H is the probability that an edge will be selected in H under the null hypothesis. The number of edges in H is σ(h) = e U X e. σ(h) has mean σ(u)p H and variance σ(u)p H (1 p H ). The statistical significance of H is Pr( σ(h) σ(h)). t is possible to estimate Pr( σ(h) σ(h)) using Chernoff bounds. We use the Central Limit Theorem: the distribution of σ(h) is approximately normal.
40 efinitions Statistical Significance: Completing the Analysis For a formula H, p H is the probability that an edge will be selected in H under the null hypothesis. The number of edges in H is σ(h) = e U X e. σ(h) has mean σ(u)p H and variance σ(u)p H (1 p H ). The statistical significance of H is Pr( σ(h) σ(h)). t is possible to estimate Pr( σ(h) σ(h)) using Chernoff bounds. We use the Central Limit Theorem: the distribution of σ(h) is approximately normal. efine the z-score z(h) of H to be z(h) = σ(h) σ(u)p H) σ(u)ph (1 p H ).
41 efinitions Statistical Significance: Completing the Analysis For a formula H, p H is the probability that an edge will be selected in H under the null hypothesis. The number of edges in H is σ(h) = e U X e. σ(h) has mean σ(u)p H and variance σ(u)p H (1 p H ). The statistical significance of H is Pr( σ(h) σ(h)). t is possible to estimate Pr( σ(h) σ(h)) using Chernoff bounds. We use the Central Limit Theorem: the distribution of σ(h) is approximately normal. efine the z-score z(h) of H to be z(h) = σ(h) σ(u)p H) σ(u)ph (1 p H ). The z-score of each formula is normally distributed with mean 0 and variance 1.
42 Algorithm Problem Complexity Number of potential formulae is exponential in the number of active networks.
43 Algorithm Problem Complexity Number of potential formulae is exponential in the number of active networks. For any threshold on statistical significance, we can construct a set of active networks for such that every possible intersection-only formula involving at least two networks has p-value at most the threshold.
44 Algorithm Problem Complexity Number of potential formulae is exponential in the number of active networks. For any threshold on statistical significance, we can construct a set of active networks for such that every possible intersection-only formula involving at least two networks has p-value at most the threshold. To make the problem tractable, we focus on constructing highly statistically significant formulae. Use the z-score as the measure for driving the algorithm.
45 Algorithm ntersection-only Algorithm: Overview Only allow the operator.
46 Algorithm ntersection-only Algorithm: Overview Only allow the operator. Algorithm is a version of bottom-up hierarchical clustering.
47 Algorithm ntersection-only Algorithm: Overview Only allow the operator. Algorithm is a version of bottom-up hierarchical clustering. nput: U is the universal network of interactions. For each cell state s, A s U is the set of all interactions active in s. A is the set of all active networks. Output: The sag formed by the union of all the formulae.
48 Algorithm ntersection-only Algorithm: Steps 1. Add each network in A as a formula to.
49 Algorithm ntersection-only Algorithm: Steps 1. Add each network in A as a formula to. 2. For every pair (F, G) of formulae in, insert the z-score z(f G) into a priority queue Q.
50 Algorithm ntersection-only Algorithm: Steps 1. Add each network in A as a formula to. 2. For every pair (F, G) of formulae in, insert the z-score z(f G) into a priority queue Q. 3. Repeatedly extract z-scores in decreasing order from Q until it becomes empty.
51 Algorithm ntersection-only Algorithm: Steps 1. Add each network in A as a formula to. 2. For every pair (F, G) of formulae in, insert the z-score z(f G) into a priority queue Q. 3. Repeatedly extract z-scores in decreasing order from Q until it becomes empty. 4. Suppose the next z-score corresponds to the formula F = G H.
52 Algorithm ntersection-only Algorithm: Steps 1. Add each network in A as a formula to. 2. For every pair (F, G) of formulae in, insert the z-score z(f G) into a priority queue Q. 3. Repeatedly extract z-scores in decreasing order from Q until it becomes empty. 4. Suppose the next z-score corresponds to the formula F = G H. 5. f G or H already has a parent in, do not consider F any further.
53 Algorithm ntersection-only Algorithm: Steps 1. Add each network in A as a formula to. 2. For every pair (F, G) of formulae in, insert the z-score z(f G) into a priority queue Q. 3. Repeatedly extract z-scores in decreasing order from Q until it becomes empty. 4. Suppose the next z-score corresponds to the formula F = G H. 5. f G or H already has a parent in, do not consider F any further. 6. Otherwise, insert F into as the parent of G and H. 7. For every formula L F, if A F A L =, insert the z-scores of F L into Q.
54 Algorithm Complete Algorithm: Steps 1. Add each network in A as a formula to. 2. For every pair (F, G) of formulae in, insert the z-score z(f G) into a priority queue Q. 3. Repeatedly extract z-scores in decreasing order from Q until it becomes empty. 4. Suppose the next z-score corresponds to the formula F = G H. 5. f G or H already has a parent in, do not consider F any further.
55 Algorithm Complete Algorithm: Steps 1. Add each network in A as a formula to. 2. For every pair (F, G) of formulae in, insert the z-score z(f G) into a priority queue Q. 3. Repeatedly extract z-scores in decreasing order from Q until it becomes empty. 4. Suppose the next z-score corresponds to the formula F = G H. 5. f G or H already has a parent in, do not consider F any further. 6. Otherwise, insert F, F 1 = G H and F 2 = H G into as the parents of G and H. and F For every formula L F, if A F A L =, insert the z-scores of F L, F 1 L, and F 2 L into Q.
56 Algorithm Post-processing the sag Compute functional enrichment of each network lego. Only keep formulae that are significant at the 0.01 level. Find true network legos: one that is more statistically significant than any of its descendants in the sag.
57 Algorithm Are Network Legos Building Blocks? f network legos are building blocks, they must be components of multiple active networks. f we remove an active network and repeat the computation, we should obtain almost the same set of network legos.
58 Algorithm Are Network Legos Building Blocks? f network legos are building blocks, they must be components of multiple active networks. f we remove an active network and repeat the computation, we should obtain almost the same set of network legos. Stability Analysis (based on Segal et al., Nature Genetics, 2004): 1. For each active network N A, compute the sag N for the set of active networks A {N}. 2. For each network lego L in, compute the most similar network lego L in N using the set-similarity measure. and store this measure with the pair σ(l, N). 3. Given a similarity threshold t, for each network lego L in, compute the fraction of networks in A such σ(l, N) t.
59 Results atasets Used Analysed data for S. cerevisiae and H. sapiens. Focus on some results for H. sapiens. H. sapiens: Wiring diagram has 9352 nodes and edges Edges in wiring diagram are protein-protein interactions (Ramani et al., Genome Biology, 2005; Rual et al., Nature, 2005; Stelzl et al., Cell, 2005, BN, HPR, REACTOME, Co-citation, Orthology) and promotor motif-based interactions (Xie et al., Nature 2005).
60 Results atasets Used Analysed data for S. cerevisiae and H. sapiens. Focus on some results for H. sapiens. H. sapiens: Wiring diagram has 9352 nodes and edges Edges in wiring diagram are protein-protein interactions (Ramani et al., Genome Biology, 2005; Rual et al., Nature, 2005; Stelzl et al., Cell, 2005, BN, HPR, REACTOME, Co-citation, Orthology) and promotor motif-based interactions (Xie et al., Nature 2005). 23 cancer-related gene expression data sets (Segal et al., Nature Genetics, 2004) spanning 92 distinct clinical conditions.
61 Results Overview of Results 92 clinical conditions yielded 298 active networks. Active networks for a single condition are edge disjoint.
62 Results Overview of Results 92 clinical conditions yielded 298 active networks. Active networks for a single condition are edge disjoint. We found 338 network legos. 227 network legos were significant at the 0.01 level and also more significant than all their descendants in the sag.
63 Results Overview of Results 92 clinical conditions yielded 298 active networks. Active networks for a single condition are edge disjoint. We found 338 network legos. 227 network legos were significant at the 0.01 level and also more significant than all their descendants in the sag. 141 statistically-significant network legos were functionally enriched in a total of 334 distinct functions. Enriched functions spanned processes involving NA replication, proteolysis, defense and immune response, cell proliferation, the cell cycle, and antigen processing.
64 Results Human Network Legos are Stable
65 Results Example of a Human Network Lego PTPRC C2 L3 L6ST C80 SPN C3Z C38 C58 FNG C4 Lung carcinoid (Lung cancer)_1 C28 LCK L4 L2 TGAL L7 FAS Lung carcinoid (Lung cancer)_2 L2RB L15 TGAM JAK3 Adenocarcinoma (Lung cancer)_1 Stage T1 (Lung cancer)_1 22 genes and 69 interactions. All interactions are supported by the literature. Enriched functions are signal transducer activity (p-value ), defense ( ), immune response ( ), and cell communication ( ).
66 Activated B like LBCL (B lymphoma)_2 Human mammary epithelial cells HMECs (Breast cancer)_4 Stimulated B cells (B lymphoma)_1 Normal lung tissue (Lung cancer)_3 Acute myelogeous leukemia (Leukemia)_6 Lung carcinoid (Lung cancer)_1 Primary blood mononuclear cells (B lymphoma)_2 Cell line (B lymphoma)_3 Epithelial cell line (NC60)_4 Activated B like LBCL (B lymphoma)_4 Atypical teratoid rhabdoid tumour CNS and other origin (Neuro tumors)_4 Adenocarcinoma periphery (Lung cancer)_1 iffuse large B cell lymphoma LBCL (B lymphoma)_3 Non small cell lung cancer (General compendium)_1 Estogen receptor (ER) positive breast cancer (Breast cancer)_2 Breast cancer (prognostic) relapse (Breast cancer)_2 nvasive liver tumor (Liver cancer)_5 Lung carcinoid (Lung cancer)_2 Acute lymphocytic leukemia ALL1 sub class (Leukemia)_4 Follicular lymphoma (B lymphoma)_2 Adenocarcinoma (Prostate cancer)_2 Small cell lung cancer (Lung cancer)_3 Squamous cell lung cancer (Lung cancer)_4 Normal lung tissue (Various tumors)_2 Melanoma (Various tumors)_1 Cell line (B lymphoma)_2 Acute lymphocytic leukemia ALL1 sub class (Leukemia)_6 Stage T2 (Lung cancer)_3 Acute lymphocytic leukemia MLL sub class (Leukemia)_2 Adenocarcinoma (Lung cancer)_1 Non classic malignant glioblastoma (Gliomas)_3 Renal tissue (Various tumors)_3 Acute lymphocytic leukemia ALL1 sub class (Leukemia)_3 Primary blood mononuclear cells (B lymphoma)_4 Stage T2 (Lung cancer)_1 Non small cell lung cancer (General compendium)_10 Activated B like LBCL (B lymphoma)_1 Adenocarcinoma extrapulmonary metastasis (Lung cancer)_2 p53 positive hepatocellular carcinoma (Liver cancer)_2 Stage T1 (Lung cancer)_1 Mesothelioma (Various tumors)_2 Adenocarcinoma (Prostate cancer)_4 Non small cell lung cancer (General compendium)_3 Breast cancer (prognostic) relapse (Breast cancer)_8 0.5hr immune stimulation (Stimulated PBMC)_1 Normal bladder tissue (Various tumors)_1 Grade 1 (Breast cancer)_1 Adenocarcinoma periphery (Lung cancer)_3 nvasive liver tumor (Liver cancer)_7 Adenocarcinoma extrapulmonary metastasis (Lung cancer)_3 Normal lung tissue (Lung cancer)_2 Normal prostate tissue (Prostate cancer)_6 Grade 3 (Breast cancer)_3 Mutated p53 tumor (Breast cancer)_4 Small cell lung cancer (Lung cancer)_2 iffuse large B cell lymphoma LBCL (B lymphoma)_5 After doxorubicin chemotherapy (Breast cancer)_1 Malignant glioblastoma (Various tumors)_3 Uterine tissue or cancer (Various tumors)_3 Normal prostate tissue (Prostate cancer)_3 iffuse large B cell lymphoma LBCL (B lymphoma)_4 T cells (Leukemia)_2 ead prognosis (Breast cancer)_2 Activated B like LBCL (B lymphoma)_5 Normal CNS tissue (Neuro tumors)_1 Malignant glioblastoma (Neuro tumors)_2 Unstimulated immune cells (Stimulated PBMC)_5 Adenocarcinoma extrapulmonary metastasis (Lung cancer)_4 Medulloblastoma (Neuro tumors)_6 Adenocarcinoma extrapulmonary metastasis (Lung cancer)_1 onomycin PMA stimulated immune cells (Stimulated PBMC)_1 Non small cell lung cancer (General compendium)_5 Colon cancer cell line (NC60)_2 Epithelial cell line (NC60)_2 Normal prostat Alive prognosis Acute myelogeous leukemia Normal tissue (Liver canc Results Example of a Human sag
67 Conclusions Features of our Approach 1. The combination of formulae, network legos, and sag appears to a novel representation of biological processes. 2. Computing active networks for each condition allows us to explicitly compare and contrast cell states via formulae and the sag. 3. Construct the sag by generalising bottom-up hierarchical clustering to graphs. 4. Computed network legos are statistically-significant, functionally-enriched, and stable.
68 Conclusions Future Research: Short Term 1. mprove network lego algorithm and statistics.
69 Conclusions Future Research: Short Term 1. mprove network lego algorithm and statistics. 2. Apply to other organisms. 3. Apply network lego without underlying wiring diagram. Problem: ActiveNetworks are very large and very dense to make sense of biologically.
70 Conclusions Future Research: Short Term 1. mprove network lego algorithm and statistics. 2. Apply to other organisms. 3. Apply network lego without underlying wiring diagram. Problem: ActiveNetworks are very large and very dense to make sense of biologically. 4. emonstrate that network legos indeed are building blocks by showing that a small number of network legos can be combined in different ways to recover the active networks.
71 Conclusions Future Research: Long Term We have not addressed a number of theoretical questions.
72 Conclusions Future Research: Long Term We have not addressed a number of theoretical questions. Complexity of generating good formulae. Conditions under which we can find good formulae efficiently. ncluding other types of operators in formulae. Efficient algorithms for enumerating all formulae. Alternative definitions of score. Formalising the notion of recovering active networks from network legos.
73 Conclusions Future Research: Long Term We have not addressed a number of theoretical questions. Complexity of generating good formulae. Conditions under which we can find good formulae efficiently. ncluding other types of operators in formulae. Efficient algorithms for enumerating all formulae. Alternative definitions of score. Formalising the notion of recovering active networks from network legos. Use network legos as the basis for discrete simulation of biological systems.
74 S. cerevisiae Wiring iagram Physical network 15,429 protein-protein interactions from the atabase of nteracting Proteins (P) protein-na interactions (Lee et al., Science, 2002). 6,306 metabolic interactions (proteins operate on at least common metabolite) based on KEGG. Genetic network 4,125 synthetically lethal/sick interactions (Tong et al., Science, 2004). 687 synthetically lethal interactions (MPS). Overall network has 32,416 (27,604 physical and 4,812 genetic) interactions between 5601 proteins (Kelley and deker, Nature Biotech., 2005).
75 Example of a S. cerevisiae Network Lego NH1 ATP1 ATP7 YGR043C ATP4 TKL2 HXK1 GLK1 ATP2 QCR6 COX4 RP1 CYB2 erisi diauxic shift COX8 GAL10 COR1 QCR2 SH4 GAL7 gasch raffinose vs reference SH2 HAP4 GAL1 COX13 SH3 QCR7 SH1 PCK1 CT1 gasch fructose vs reference gasch glucose vs reference N1 NE1
Inferring Biological Meaning from Cap Analysis Gene Expression Data
Inferring Biological Meaning from Cap Analysis Gene Expression Data HRYSOULA PAPADAKIS 1. Introduction This project is inspired by the recent development of the Cap analysis gene expression (CAGE) method,
More informationVL Network Analysis ( ) SS2016 Week 3
VL Network Analysis (19401701) SS2016 Week 3 Based on slides by J Ruan (U Texas) Tim Conrad AG Medical Bioinformatics Institut für Mathematik & Informatik, Freie Universität Berlin 1 Motivation 2 Lecture
More informationNature Getetics: doi: /ng.3471
Supplementary Figure 1 Summary of exome sequencing data. ( a ) Exome tumor normal sample sizes for bladder cancer (BLCA), breast cancer (BRCA), carcinoid (CARC), chronic lymphocytic leukemia (CLLX), colorectal
More informationGene-microRNA network module analysis for ovarian cancer
Gene-microRNA network module analysis for ovarian cancer Shuqin Zhang School of Mathematical Sciences Fudan University Oct. 4, 2016 Outline Introduction Materials and Methods Results Conclusions Introduction
More informationA holistic approach to targeting breast cancer part II: Micronutrient synergy. Presented by: Dr. Neha Shanker DRRI
A holistic approach to targeting breast cancer part II: Micronutrient synergy Presented by: Dr. Neha Shanker DRRI Overview of the previous webinar In the last presentation we talked about: Increase in
More informationReview (V1) - The Hallmarks of Cancer
Review (V1) - The Hallmarks of Cancer Robert A. Weinberg 1 Review (V1) - The Hallmarks of Cancer 2 Review (V1) - Number of somatic mutations in human cancers Top: children vs. adults Numbers in parentheses
More informationPresentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98
Presentation material is for education purposes only. All rights reserved. 2011 URMC Radiology Page 1 of 98 Radiology / Pathology Conference February 2011 Brooke Koltz, Cytopathology Resident Presentation
More informationCancer. Questions about cancer. What is cancer? What causes unregulated cell growth? What regulates cell growth? What causes DNA damage?
Questions about cancer What is cancer? Cancer Gil McVean, Department of Statistics, Oxford What causes unregulated cell growth? What regulates cell growth? What causes DNA damage? What are the steps in
More informationThe 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis
The 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis Tieliu Shi tlshi@bio.ecnu.edu.cn The Center for bioinformatics
More informationUrinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
More informationProbabilistic retrieval and visualization of relevant experiments
Probabilistic retrieval and visualization of relevant experiments Samuel Kaski Joint work with: José Caldas, Nils Gehlenborg, Ali Faisal, Alvis Brazma Motivation 2 How to best use collections of measurement
More informationCODING TUMOUR MORPHOLOGY. Otto Visser
CODING TUMOUR MORPHOLOGY Otto Visser INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show
More informationSUPPLEMENTARY MATERIAL
SUPPLEMENTARY MATERIAL Supplementary Figure 1. Recursive partitioning using PFS data in patients with advanced NSCLC with non-squamous histology treated in the placebo pemetrexed arm of LUME-Lung 2. (A)
More informationMore Examples and Applications on AVL Tree
CSCI2100 Tutorial 11 Jianwen Zhao Department of Computer Science and Engineering The Chinese University of Hong Kong Adapted from the slides of the previous offerings of the course Recall in lectures we
More informationHoare Logic and Model Checking. LTL and CTL: a perspective. Learning outcomes. Model Checking Lecture 12: Loose ends
Learning outcomes Hoare Logic and Model Checking Model Checking Lecture 12: Loose ends Dominic Mulligan Based on previous slides by Alan Mycroft and Mike Gordon Programming, Logic, and Semantics Group
More informationReview (V1) - The Hallmarks of Cancer
Review (V1) - The Hallmarks of Cancer Robert A. Weinberg 1 Review (V1) - The Hallmarks of Cancer 2 Review (V1) - Number of somatic mutations in human cancers Top: children vs. adults Numbers in parentheses
More informationMicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL
MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationPatient characteristics of training and validation set. Patient selection and inclusion overview can be found in Supp Data 9. Training set (103)
Roepman P, et al. An immune response enriched 72-gene prognostic profile for early stage Non-Small- Supplementary Data 1. Patient characteristics of training and validation set. Patient selection and inclusion
More informationWhat is Cancer? Understanding the basics of
What is Cancer? Understanding the basics of A process of physical and biological changes that occur when normal healthy cells are transformed into cancer cells What is Cancer? Cancer is an umbrella term
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationCancer in Ireland with estimates for
Cancer in Ireland 1994-2015 with estimates for 2015-2017: Annual Report of the National Cancer Registry 2017 Page ABBREVIATIONS 95% CI 95% confidence interval APC Annual percentage change ASR Age-standardised
More informationMBios 478: Systems Biology and Bayesian Networks, 27 [Dr. Wyrick] Slide #1. Lecture 27: Systems Biology and Bayesian Networks
MBios 478: Systems Biology and Bayesian Networks, 27 [Dr. Wyrick] Slide #1 Lecture 27: Systems Biology and Bayesian Networks Systems Biology and Regulatory Networks o Definitions o Network motifs o Examples
More informationGene Ontology and Functional Enrichment. Genome 559: Introduction to Statistical and Computational Genomics Elhanan Borenstein
Gene Ontology and Functional Enrichment Genome 559: Introduction to Statistical and Computational Genomics Elhanan Borenstein The parsimony principle: A quick review Find the tree that requires the fewest
More informationTumour Structure and Nomenclature. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge
Tumour Structure and Nomenclature Paul Edwards Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Malignant Metastasis Core idea of cancer Normal Cell Slightly
More informationChapter 1. Introduction
Chapter 1 Introduction 1.1 Motivation and Goals The increasing availability and decreasing cost of high-throughput (HT) technologies coupled with the availability of computational tools and data form a
More informationHuman cell line list Production of Exosome Standards - Cell Lysates
Human cell line list 2016 - Production of Exosome Standards - Cell Lysates 380 peripheral blood leukemia, pre-b cell 1301 blood leukemia, acute lymphoblastic, T cell 5637 bladder carcinoma 8305C thyroid
More informationUpdate on Colorectal Cancer: Integrating the Host Immune Response 3 rd Emirates Surgical Pathology Conference 15 December 2017 Dubai, UAE
Update on Colorectal Cancer: Integrating the Host Immune Response 3 rd Emirates Surgical Pathology Conference 15 December 2017 Dubai, UAE Martine McManus, MD, FCAP Pathology & Laboratory Medicine Institute
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationCharacteristics of Cancer Stem Cells (CSCs)
GENReports: Market & Tech Analysis Characteristics of Cancer Stem Cells (CSCs) > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director Select Biosciences, Inc. enal@selectbio.us! Topic,IntroducEon,and,Scope!
More information# Assessment of gene expression levels between several cell group types is a common application of the unsupervised technique.
# Aleksey Morozov # Microarray Data Analysis Using Hierarchical Clustering. # The "unsupervised learning" approach deals with data that has the features X1,X2...Xp, but does not have an associated response
More informationQuiz. b. 4 High grade c. 9 Unknown
Quiz 1. 10/11/12 CT scan abdomen/pelvis: Metastatic liver disease with probable primary colon malignancy. 10/17/12 Colonoscopy with polypectomy: Adenocarcinoma of sigmoid colon measuring at least 6 mm
More informationBY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,
More informationOverview on kidney exchange programs
Overview on kidney exchange programs Ana Viana et al ana.viana@inesctec.pt 11 March 2016 Outline Kidney failure: some figures. The past: deceased and living donor transplants. The present: Kidney exchange
More informationOutcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures. Because we are an accredited
More informationGenomic analysis of essentiality within protein networks
Genomic analysis of essentiality within protein networks Haiyuan Yu, Dov Greenbaum, Hao Xin Lu, Xiaowei Zhu and Mark Gerstein Department of Molecular Biophysics and Biochemistry, 266 Whitney Avenue, Yale
More informationUnderstandable Statistics
Understandable Statistics correlated to the Advanced Placement Program Course Description for Statistics Prepared for Alabama CC2 6/2003 2003 Understandable Statistics 2003 correlated to the Advanced Placement
More informationRecent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
More informationSupplementary Materials for
Supplementary Materials for A Clinical Trial for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes Not Eligible for Standard Clinical Trials Table of Contents Content Page Supplementary
More informationOutcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
More informationBayesian Prediction Tree Models
Bayesian Prediction Tree Models Statistical Prediction Tree Modelling for Clinico-Genomics Clinical gene expression data - expression signatures, profiling Tree models for predictive sub-typing Combining
More informationSession 4 Rebecca Poulos
The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 20
More informationBiochemistry of Carcinogenesis. Lecture # 35 Alexander N. Koval
Biochemistry of Carcinogenesis Lecture # 35 Alexander N. Koval What is Cancer? The term "cancer" refers to a group of diseases in which cells grow and spread unrestrained throughout the body. It is difficult
More informationSSM signature genes are highly expressed in residual scar tissues after preoperative radiotherapy of rectal cancer.
Supplementary Figure 1 SSM signature genes are highly expressed in residual scar tissues after preoperative radiotherapy of rectal cancer. Scatter plots comparing expression profiles of matched pretreatment
More informationKnockdown of Malic Enzyme 2 Suppresses Lung Tumor Growth, Induces Differentiation and Impacts PI3K/AKT Signaling
SUPPLEMENTARY INFORMATION Knockdown of Malic Enzyme 2 Suppresses Lung Tumor Growth, Induces Differentiation and Impacts PI3K/AKT Signaling Jian-Guo Ren 1, Pankaj Seth 1, Clary B. Clish 2, Pawel K. Lorkiewicz
More informationNew Developments in Cancer Treatment. Ian Rabinowitz MD
New Developments in Cancer Treatment Ian Rabinowitz MD Treatment Outline Angiogenesis inhibition Targeted therapy Immunotherapy Personalization of therapy Genomics and cancer Stem cells and cancer Angiogenesis
More informationInference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics, 2010
Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics, 2010 C.J.Vaske et al. May 22, 2013 Presented by: Rami Eitan Complex Genomic
More informationOverview of Cancer. Mylene Freires Advanced Nurse Practitioner, Haematology
Overview of Cancer Mylene Freires Advanced Nurse Practitioner, Haematology Aim of the Presentation Review basic concepts of cancer Gain some understanding of the socio-economic impact of cancer Order of
More informationBayesian (Belief) Network Models,
Bayesian (Belief) Network Models, 2/10/03 & 2/12/03 Outline of This Lecture 1. Overview of the model 2. Bayes Probability and Rules of Inference Conditional Probabilities Priors and posteriors Joint distributions
More informationChapter 1: Exploring Data
Chapter 1: Exploring Data Key Vocabulary:! individual! variable! frequency table! relative frequency table! distribution! pie chart! bar graph! two-way table! marginal distributions! conditional distributions!
More informationBIT 120. Copy of Cancer/HIV Lecture
BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations
More informationCancer statistics (US)
Disclosure I have no financial relationships to disclose Biology and Introduction to the Genetics of Cancer Vickie Matthias Hagen, MS, CGC Certified Genetic Counselor Virginia Piper Cancer Service Line
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationFACULTY MEMBERSHIP APPLICATION Tulane Cancer Center
FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center 1430 Tulane Ave., Box SL-68, New Orleans, LA 70112-2699 J. Bennett Johnston Building, Mezzanine (Floor 1A), Suite A102 (504) 988-6060, fax (504) 988-6077,
More informationnumber Done by Corrected by Doctor Maha Shomaf
number 19 Done by Waseem Abo-Obeida Corrected by Abdullah Zreiqat Doctor Maha Shomaf Carcinogenesis: the molecular basis of cancer. Non-lethal genetic damage lies at the heart of carcinogenesis and leads
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More information(14R)-14-hydroxy-4,14-retroretinol (14-HRR)
Table S7 Atypical retinoids and retinoid-related molecules (RRMs) ame Chemical structure of the ligand(s) Mechanism of action and uses References Anhydroretinol (AR) Modulators of c-raf kinase 1-3 Blocks
More informationSupplementary Figures
Supplementary Figures Supplementary Figure 1. Pan-cancer analysis of global and local DNA methylation variation a) Variations in global DNA methylation are shown as measured by averaging the genome-wide
More informationClassification of cancer profiles. ABDBM Ron Shamir
Classification of cancer profiles 1 Background: Cancer Classification Cancer classification is central to cancer treatment; Traditional cancer classification methods: location; morphology, cytogenesis;
More informationTumours in the donor: what is the risk?
Tumours in the donor: what is the risk? Pr Olivier Detry Dpt of Abdominal Surgery & Transplanta@on CHU Liège, University of Liege, Belgium olivier.detry@transplanta@on.be Financial Disclosure Research
More informationNOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R)
Item 18-13c NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May 2013 BREAST CANCER MCN: Breast Disease: Breast Document ready to circulate lead to be discussed
More informationDr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology
Neoplasia Dr Rodney Itaki Lecturer Anatomical Pathology Discipline University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology General Considerations Overview: Neoplasia uncontrolled,
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationCancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous
Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors
More informationComparison of discrimination methods for the classification of tumors using gene expression data
Comparison of discrimination methods for the classification of tumors using gene expression data Sandrine Dudoit, Jane Fridlyand 2 and Terry Speed 2,. Mathematical Sciences Research Institute, Berkeley
More informationExpanded View Figures
Molecular Systems iology Tumor CNs reflect metabolic selection Nicholas Graham et al Expanded View Figures Human primary tumors CN CN characterization by unsupervised PC Human Signature Human Signature
More informationNature Genetics: doi: /ng Supplementary Figure 1
Supplementary Figure 1 Expression deviation of the genes mapped to gene-wise recurrent mutations in the TCGA breast cancer cohort (top) and the TCGA lung cancer cohort (bottom). For each gene (each pair
More informationTable of content. -Supplementary methods. -Figure S1. -Figure S2. -Figure S3. -Table legend
Table of content -Supplementary methods -Figure S1 -Figure S2 -Figure S3 -Table legend Supplementary methods Yeast two-hybrid bait basal transactivation test Because bait constructs sometimes self-transactivate
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationComputer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015
Goals/Expectations Computer Science, Biology, and Biomedical (CoSBBI) We want to excite you about the world of computer science, biology, and biomedical informatics. Experience what it is like to be a
More informationNetwork-assisted data analysis
Network-assisted data analysis Bing Zhang Department of Biomedical Informatics Vanderbilt University bing.zhang@vanderbilt.edu Protein identification in shotgun proteomics Protein digestion LC-MS/MS Protein
More informationIntroduction. Introduction
Introduction We are leveraging genome sequencing data from The Cancer Genome Atlas (TCGA) to more accurately define mutated and stable genes and dysregulated metabolic pathways in solid tumors. These efforts
More informationDATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #
DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #2006-01 CATEGORY: CLARIFICATION SUBJECT: RESCINDMENT - DSQC MEMORANDUM 2002-08 Coding Complex Morphologic Diagnoses (revised 8/02) EFFECTIVE: For Cases
More informationIntegrative analysis of survival-associated gene sets in breast cancer
Varn et al. BMC Medical Genomics (2015) 8:11 DOI 10.1186/s12920-015-0086-0 RESEARCH ARTICLE Open Access Integrative analysis of survival-associated gene sets in breast cancer Frederick S Varn 1, Matthew
More informationAllinaHealthSystems 1
Overview Biology and Introduction to the Genetics of Cancer Denise Jones, MS, CGC Certified Genetic Counselor Virginia Piper Cancer Service Line I. Our understanding of cancer the historical perspective
More informationCase Studies on High Throughput Gene Expression Data Kun Huang, PhD Raghu Machiraju, PhD
Case Studies on High Throughput Gene Expression Data Kun Huang, PhD Raghu Machiraju, PhD Department of Biomedical Informatics Department of Computer Science and Engineering The Ohio State University Review
More informationPredicting Kidney Cancer Survival from Genomic Data
Predicting Kidney Cancer Survival from Genomic Data Christopher Sauer, Rishi Bedi, Duc Nguyen, Benedikt Bünz Abstract Cancers are on par with heart disease as the leading cause for mortality in the United
More informationCODING STAGE: TNM AND OTHER STAGING SYSTEMS. Liesbet Van Eycken Otto Visser
CODING STAGE: TNM AND OTHER STAGING SYSTEMS Liesbet Van Eycken Otto Visser OVERVIEW PART I Introduction What is stage? Why stage? History and publications of TNM Classification Clinical and pathologic
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM BRAIN METASTASES CNS Site Group Brain Metastases Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationDifferent Types of Cancer
Different Types of Cancer Cancer can originate almost anywhere in the body. Sarcomas (connective tissue) Ø arise from cells found in the supporting tissues of the body such as bone, cartilage, fat, connective
More informationDr. Bernard Huber CEO. Bio-Europe
Dr. Bernard Huber CEO Bio-Europe 2015 1 ORYX Overview ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007 and located in Baldham/Munich, Germany ORYX bridges
More informationCorporate Medical Policy
Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationFuzzy Decision Tree FID
Fuzzy Decision Tree FID Cezary Z. Janikow Krzysztof Kawa Math & Computer Science Department Math & Computer Science Department University of Missouri St. Louis University of Missouri St. Louis St. Louis,
More informationWDHS Curriculum Map Probability and Statistics. What is Statistics and how does it relate to you?
WDHS Curriculum Map Probability and Statistics Time Interval/ Unit 1: Introduction to Statistics 1.1-1.3 2 weeks S-IC-1: Understand statistics as a process for making inferences about population parameters
More informationInterpreting Diverse Genomic Data Using Gene Sets
Interpreting Diverse Genomic Data Using Gene Sets giovanni parmigiani@dfci.harvard.edu FHCRC February 2012 Gene Sets Leary 2008 PNAS Alterations in the combined FGF, EGFR, ERBB2 and PIK3 pathways. Red:
More informationIdentification of Tissue Independent Cancer Driver Genes
Identification of Tissue Independent Cancer Driver Genes Alexandros Manolakos, Idoia Ochoa, Kartik Venkat Supervisor: Olivier Gevaert Abstract Identification of genomic patterns in tumors is an important
More informationAgent-Based Models. Maksudul Alam, Wei Wang
Agent-Based Models Maksudul Alam, Wei Wang Outline Literature Review about Agent-Based model Modeling disease outbreaks in realistic urban social Networks EpiSimdemics: an Efficient Algorithm for Simulating
More informationIntron A. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Page: 1 of 6 Last Review Date: June 19, 2015 Intron A Description Intron A (interferon
More informationmaintrac What's the future in precision diagnostics? From screening to stem cells and back!
maintrac What's the future in precision diagnostics? From screening to stem cells and back! Cancer is a frightening diagnosis: why? Malignant tumours are detectable when they have reached a size of about
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationHarmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY
Harmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY A NEW GENE A DAY.WHILE YOU ARE ENJOYING MORNING COFFEE From cancer.gov GOALS FOR THE CME TODAY A brief
More informationTumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
More informationCancer in the organ donor
Cancer in the organ donor Pr Olivier Detry Dpt of Abdominal Surgery & Transplanta>on CHU Liège, University of Liege, Belgium olivier.detry@transplanta>on.be Conflicts of Interest Conflicts of Interest
More informationModule 3: Pathway and Drug Development
Module 3: Pathway and Drug Development Table of Contents 1.1 Getting Started... 6 1.2 Identifying a Dasatinib sensitive cancer signature... 7 1.2.1 Identifying and validating a Dasatinib Signature... 7
More informationTranscript-indexed ATAC-seq for immune profiling
Transcript-indexed ATAC-seq for immune profiling Technical Journal Club 22 nd of May 2018 Christina Müller Nature Methods, Vol.10 No.12, 2013 Nature Biotechnology, Vol.32 No.7, 2014 Nature Medicine, Vol.24,
More informationThe Cancer Genome Atlas Pan-cancer analysis Katherine A. Hoadley
The Cancer Genome Atlas Pan-cancer analysis Katherine A. Hoadley Department of Genetics Lineberger Comprehensive Cancer Center The University of North Carolina at Chapel Hill What is TCGA? The Cancer Genome
More informationTest Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar
Link full download: http://testbankair.com/download/test-bank-for-robbins-cotran-pathologic-basis-of-disease-9th-edition-bykumar-abbas-and-aster Test Bank for Robbins and Cotran Pathologic Basis of Disease
More informationLecture 1: Carcinogenesis
Lecture 1: Carcinogenesis Anti-cancer (oncology agents): These are perhaps the most dangerous of drugs, other than the narcotic analgesics. This is due to their toxicities. Killing or inhibiting cancer
More information